Milatuzumab
As of the edition of 20 October 2026, Milatuzumab is an antibody: stopped in 2017; acts on CD74.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2017
- Kind
- Antibody
- Registered trials
- 8, 2 stopped early
- Disease areas
- Immune system; Blood and lymph; Cancer; Heart and blood vessels; Infections; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Milatuzumab.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD74 | HLA class II histocompatibility antigen gamma chain | P04233 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 2 | 0 | 1 |
| Phase 2 | 5 | 3 | 0 | 1 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Gilead Sciences | Lead sponsor of trials | 2007 to now |